Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vibeke Strand

Showing results (261-270 of 435) with videos related to

Pageof 44
Sort By:
Postgraduate Medicine|April 28, 2015
Low-dose SoluMatrix diclofenac in the treatment of osteoarthritis: A 1-year, open-label, Phase III safety studyRoy D Altman, Vibeke Strand, Marc C Hochberg, et al.
Nature Reviews. Disease Primers|February 9, 2018
Rheumatoid arthritisJosef S Smolen, Daniel Aletaha, Anne Barton, et al.
The Journal of Rheumatology|June 17, 2017
Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group ReportNatalia V Zamora, Robin Christensen, Niti Goel, et al.
RMD Open|February 5, 2019
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugsVibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, et al.
Arthritis Research & Therapy|December 17, 2015
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trialsVibeke Strand, Sima Ahadieh, Jonathan French, et al.
Rheumatology (Oxford, England)|December 13, 2021
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 programCharles G Peterfy, Vibeke Strand, Alan Friedman, et al.
Arthritis Research & Therapy|April 9, 2020
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomesCem Gabay, Gerd R Burmester, Vibeke Strand, et al.
The Journal of Rheumatology|May 8, 2003
MCID/Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritisGeorge Wells, Maarten Boers, Beverley Shea, et al.
Arthritis and Rheumatism|July 19, 2002
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trialMichelle A Petri, Robert G Lahita, Ronald F Van Vollenhoven, et al.
The Journal of Rheumatology|July 5, 2011
Toward development of a fibromyalgia responder index and disease activity score: OMERACT module updatePhilip J Mease, Daniel J Clauw, Robin Christensen, et al.
Pageof 44

Showing results (261-270 of 435) with videos related to

Sort By:
Pageof 44
Postgraduate Medicine|April 28, 2015
Low-dose SoluMatrix diclofenac in the treatment of osteoarthritis: A 1-year, open-label, Phase III safety studyRoy D Altman, Vibeke Strand, Marc C Hochberg, et al.
Nature Reviews. Disease Primers|February 9, 2018
Rheumatoid arthritisJosef S Smolen, Daniel Aletaha, Anne Barton, et al.
The Journal of Rheumatology|June 17, 2017
Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group ReportNatalia V Zamora, Robin Christensen, Niti Goel, et al.
RMD Open|February 5, 2019
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugsVibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, et al.
Arthritis Research & Therapy|December 17, 2015
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trialsVibeke Strand, Sima Ahadieh, Jonathan French, et al.
Rheumatology (Oxford, England)|December 13, 2021
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 programCharles G Peterfy, Vibeke Strand, Alan Friedman, et al.
Arthritis Research & Therapy|April 9, 2020
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomesCem Gabay, Gerd R Burmester, Vibeke Strand, et al.
The Journal of Rheumatology|May 8, 2003
MCID/Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritisGeorge Wells, Maarten Boers, Beverley Shea, et al.
Arthritis and Rheumatism|July 19, 2002
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trialMichelle A Petri, Robert G Lahita, Ronald F Van Vollenhoven, et al.
The Journal of Rheumatology|July 5, 2011
Toward development of a fibromyalgia responder index and disease activity score: OMERACT module updatePhilip J Mease, Daniel J Clauw, Robin Christensen, et al.
Pageof 44